Safety and Efficacy of the ISS Sleeve Augmentation Technique in the Treatment of Thoracolumbar Osteopenic Fractures

Inclusion Criteria: Patient 1. Age ≥ 50 and ≤ 85, male and female patients 2. Subject is able to understand the risks and benefits of participating in the study and is willing to provide written informed consent. 3. Psychosocially, mentally and physically able to fully comply with the protocol requirements for the duration of the study including adhering to scheduled visits, treatment plan, completing forms and other study procedures. Fracture 4. Fractures between the 10th thoracic and 4th lumbar vertebra, both included 5. Bone mineral density equal or above the threshold of 60 mgHA/ccm (central assessment of the screening qCT scan). 6. Fractures with the indication and possibility for augmented bi-segmental dorsal pedicle screw and rod stabilization including kyphoplasty in the broken vertebra 7. All fractures where pedicle screws can be used Exclusion Criteria: Patient 1. Substance use disorders (incl. tobacco abuse \>20 cigarettes/day) and alcohol abuse disorders within the last 2 years before randomization. 2. BMI \> 35 3. Permanent or progressive neurologic deficits (incl. upper motor neuron disease and myelopathy) 4. Known Creutzfeldt Jacob Disease 5. Systemic infections: * Known infection with human immunodeficiency virus (HIV) or, hepatitis B or C requiring treatment * Any active infection requiring the use of parenteral anti-microbial agents or that is \> grade 2 Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 6. Rheumatoid arthritis or known disorders of bone metabolism (excl. osteopenia/osteoporosis, Vitamin D deficiency) 7. Radiation therapy of the spine in medical history 8. Contraindications to pedicle screw and rod stabilization 9. Breast feeding, pregnancy or child-bearing potential (female patients of childbearing potential and male patients with a partner of child bearing potential must agree to use a highly effective contraceptive method). 10. A compromised immune system or a therapy with systemic corticosteroids or immunosuppressants 11. Active malignancy or history of malignancy (excl. Basalioma as a semi-malignant tumor) \<2 years ago from time of randomization 12. Known allergy to any component of the investigational device 13. History of severe allergy, anaphylactic reactions and hypersensitivity reactions experienced in previous surgical interventions. 14. Other concurrent severe and/or uncontrolled medical conditions (e.g. insufficiently treated diabetes (HbA1c \> 8 %), active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol 15. Participation in other clinical investigations for drugs or devices Fracture 16. Fracture age \> 3 months 17. Major surgery to the spine planned for at least 12 months following enrolment 18. Any treatment of the fracture other than that specified in the inclusion criteria (e.g. index screws in the fractured vertebra, vertebroplasty, additional ventral stabilization) 19. Severe spinal deformations or fusion at the target vertebral or adjacent segments 20. Previous operations at the spine in the target or adjacent vertebrae 21. Infections or inflammatory processes at vertebral bodies